AI Expanded Access Growth equity funding and AI-driven platform development indicate a strong trajectory for scalable pre-approval access solutions. This presents a sales opportunity to offer enhanced AI-enabled patient matching, trial recruitment optimization, and expanded access program management to sustain and accelerate their platform adoption.

Global Platform Active offices in Amsterdam, New York and India with global operations imply a need for cross-border trial support, regulatory navigation, logistics, and real-world data capabilities across multiple markets. Target partnerships or tiered service packages that streamline international expanded access and multi-country trial enrollment.

Clinical Trial Enablement Extensive work with patients, physicians, and BioPharma clients around pre-approval options suggests opportunities to upsell comprehensive recruitment services, patient navigator enhancements, and real‑world data collection solutions to inform trial design and post‑approval strategies.

AI Platform Expansion Recent launches of AI-enhanced Expanded Access SaaS and ongoing AI-driven platform development signal readiness for advanced analytics, predictive matching, and automation features. Propose integrated modules for site selection, patient outreach optimization, and compliance monitoring to drive adoption with pharma sponsors.

Strategic Partnerships Recent collaborations with Icanbwell, Rare Disease Research, Scout Clinical and Avego funding activity indicate a pattern of ecosystem building. Position co-sell opportunities around joint go-to-market with biopharma, CROs, and patient advocacy groups to broaden reach and accelerate revenue.